Skip to content
Live From WCLC 2024: Sunday Highlights episode artwork

Sep 8, 2024 33 min

Live From WCLC 2024: Sunday Highlights

from Lung Cancer Considered Hosted by IASLC

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Stephen Liu discusses daily highlights from the conference. Dr. Caicun Zhou discusses the results of ivonescimab versus pembrolizumab in the first-line HARMONi-2 study. Dr. Tina Cascone discusses preliminary outcomes from the perioperative NeoCOAST-2 study, and Dr. Marina Chiara Garassino outlines the potential QCS-NMR TROP2 biomarker using data from TROPION-Lung01. Dr. Matthew Smeltzer shares the results of the 2024 IASLC Global Survey on Biomarker Testing and how they compare to findings from the previous survey in 2018. Guests: Dr. Tina Cascone Physician-Scientist and Associate Professor, Department of Thoracic/Head and Neck Medical Oncology University of Texas MD Anderson Cancer Center in Houston, Texas Dr. Marina Chiara Garassino Director, Thoracic Oncology Program and Professor of Medicine University of Chicago Dr. Matthew Smeltzer Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health University of Memphis Professor Caicun Zhou Chief Physician and Director of the Department of Medical Oncology Tongji University in Shanghai Pulmonary Hospital

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Live From WCLC 2024: Sunday Highlights

0:00 33:34

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Lung Cancer Considered?

This episode is 33 minutes long.

When was this Lung Cancer Considered episode published?

This episode was published on September 8, 2024.

Can I download this Lung Cancer Considered episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.